{"id":"12b1a23d-9661-56d3-b691-db42546c67a1","stable_key":"3238e4f0-8d45-5c72-8624-6e9a8b20527c:ibu-most-nsaids-favour-cox1","predicate":"is_inhibited_by","statement":"Incubation of human mononuclear cells with lipopolysaccharide induced a time-dependent increase in cyclooxygenase-2 protein of more than a hundredfold at 24 hours with increased prostaglandin E2 production, while cyclooxygenase-1 protein was present at time zero and not induced, and most non-steroidal anti-inflammatory drugs are more potent at inhibiting cyclooxygenase-1 than cyclooxygenase-2, with five experimental compounds showing greater selectivity for cyclooxygenase-2.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"negative","is_public":true,"mechanism_event_id":"5c26839e-bda4-5ac3-b16a-21f9d22a599b","mechanism_event_label":"The first enzyme is always there and the second one appears when tissue is provoked; most of these drugs hit the first harder.","subject":{"id":"6284d26c-01e2-5e12-b192-ee391dd107e2","slug":"ptgs1","display_name":"Cyclooxygenase-1 (PTGS1)","entity_type_key":"protein"},"object":{"id":"b429f269-1d01-59f4-881a-868de0849d0d","slug":"ibuprofen","display_name":"Ibuprofen","entity_type_key":"drug"},"evidence_count":1,"mechanism_event":{"id":"5c26839e-bda4-5ac3-b16a-21f9d22a599b","stable_key":"3238e4f0-8d45-5c72-8624-6e9a8b20527c:ibu-most-nsaids-favour-cox1-event","event_type":"observed_intervention","label":"The first enzyme is always there and the second one appears when tissue is provoked; most of these drugs hit the first harder.","description":"Incubation of human mononuclear cells with lipopolysaccharide induced a time-dependent increase in cyclooxygenase-2 protein of more than a hundredfold at 24 hours with increased prostaglandin E2 production, while cyclooxygenase-1 protein was present at time zero and not induced, and most non-steroidal anti-inflammatory drugs are more potent at inhibiting cyclooxygenase-1 than cyclooxygenase-2, with five experimental compounds showing greater selectivity for cyclooxygenase-2.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"c8a31ed4-f2ca-5d43-8352-e9935129a785","slug":"ptgs2","display_name":"Cyclooxygenase-2 (PTGS2)","entity_type_key":"protein"},"role":"induced_isoform","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"5733d7d1-6259-588f-a4a9-4d0dc0133735","slug":"prostaglandin-e2","display_name":"Prostaglandin E2","entity_type_key":"small_molecule"},"role":"isoform_index","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"3b200ef2-893f-5ca7-93f4-ea657577a760","slug":"thromboxane-b2","display_name":"Thromboxane B2","entity_type_key":"small_molecule"},"role":"isoform_index","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"34983199-a31e-5364-9caf-b530d5ee2c99","slug":"whole-blood-assay","display_name":"The human whole blood assay of cyclooxygenase activity","entity_type_key":"cellular_process"},"role":"method","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""},{"entity":{"id":"6284d26c-01e2-5e12-b192-ee391dd107e2","slug":"ptgs1","display_name":"Cyclooxygenase-1 (PTGS1)","entity_type_key":"protein"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":4,"notes":""},{"entity":{"id":"b429f269-1d01-59f4-881a-868de0849d0d","slug":"ibuprofen","display_name":"Ibuprofen","entity_type_key":"drug"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":5,"notes":""}]},"contexts":[{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/ibuprofen-research/8907587.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"99f3a26e6399b5f81c18859b9f62eafcd7aa6fc4e483d97a39e8c35c060a9d75\", \"start_char\": 0, \"end_char\": 1101, \"text_sha256\": \"99f3a26e6399b5f81c18859b9f62eafcd7aa6fc4e483d97a39e8c35c060a9d75\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Lipopolysaccharide-challenged human whole blood with prostaglandin E2 and thromboxane B2 as isoform indices","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Lipopolysaccharide induction of cyclooxygenase-2 with a single oral indomethacin dose ex vivo","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Establishes the assay the other records rely on. Indomethacin rather than ibuprofen is the drug dosed here.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Ibuprofen research collection; topical membership is not evidence of a direct clinical effect, and the racemate is recorded separately from each of its two enantiomers.","comparator":null,"unit":null,"notes":"","entity":{"slug":"ibuprofen","display_name":"Ibuprofen","entity_type_key":"drug"}},{"dimension":"organism","value_text":"Human","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"The first enzyme is always there and the second one appears when tissue is provoked; most of these drugs hit the first harder.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[ibu-p8907587] A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors. (1996). https://pubmed.ncbi.nlm.nih.gov/8907587/ DOI: 10.1007/bf02265118","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Whole blood and mononuclear cells","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"b5b97c7e-e84c-5474-b3fd-517c5fae9068","evidence_kind":"source_excerpt","locator":"Lines 357-368","start_line":357,"end_line":368,"excerpt":"### ibu-most-nsaids-favour-cox1\nIncubation of human mononuclear cells with lipopolysaccharide induced a time-dependent increase in cyclooxygenase-2 protein of more than a hundredfold at 24 hours with increased prostaglandin E2 production, while cyclooxygenase-1 protein was present at time zero and not induced, and most non-steroidal anti-inflammatory drugs are more potent at inhibiting cyclooxygenase-1 than cyclooxygenase-2, with five experimental compounds showing greater selectivity for cyclooxygenase-2.\nCondition category: normal\nnutrient_topic: Ibuprofen research collection; topical membership is not evidence of a direct clinical effect, and the racemate is recorded separately from each of its two enantiomers.\nplain_language: The first enzyme is always there and the second one appears when tissue is provoked; most of these drugs hit the first harder.\norganism: Human\ntissue_or_cell_type: Whole blood and mononuclear cells\nexperimental_model: Lipopolysaccharide-challenged human whole blood with prostaglandin E2 and thromboxane B2 as isoform indices\nlimitations: Establishes the assay the other records rely on. Indomethacin rather than ibuprofen is the drug dosed here.\nexposure: Lipopolysaccharide induction of cyclooxygenase-2 with a single oral indomethacin dose ex vivo\nevidence_span: {\"source_cache\": \"artifacts/ibuprofen-research/8907587.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"99f3a26e6399b5f81c18859b9f62eafcd7aa6fc4e483d97a39e8c35c060a9d75\", \"start_char\": 0, \"end_char\": 1101, \"text_sha256\": \"99f3a26e6399b5f81c18859b9f62eafcd7aa6fc4e483d97a39e8c35c060a9d75\"}\n[ibu-p8907587] A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors. (1996). https://pubmed.ncbi.nlm.nih.gov/8907587/ DOI: 10.1007/bf02265118","model_system":"Lipopolysaccharide-challenged human whole blood with prostaglandin E2 and thromboxane B2 as isoform indices","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [ibu-p8907587] A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors. (1996). https://pubmed.ncbi.nlm.nih.gov/8907587/ DOI: 10.1007/bf02265118","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"31c4939d-f520-55c0-973b-224743caf245","stable_key":"import-3238e4f0-8d45-5c72-8624-6e9a8b20527c","title":"Ibuprofen: the enantiomer that works, the one that was called inactive, the one-way chemistry that turns one into the other, and the targets that are not cyclooxygenase (2026-09-22)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"cc2b388178f97f5906b66ecbe441fc5c86d51fd645947c5260fb0b4bdb4bcd21","revision_id":"0b4e5c65-05d3-5430-a4cd-8d6a03647dcb","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}